Moreover, invasive CD133+ stem-like cells isolated from pancreatic cancer cell lines displayed higher expression levels of gene involved in the BRCA1-mediated DNA repair pathway and resistance to gemcitabine (GEM) treatment compared to CD133- subpopulation (65). This evidence concerns the gene PROM1 and familial pancreatic carcinoma.